



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 21-976/S-012  
NDA 21-976/S-013

**SUPPLEMENT APPROVAL**

Tibotec Incorporated  
Attention: Susan Fiordeliso  
Manager, Global Regulatory Affairs  
1020 Stony Hill Road, Suite 300  
Yardley, PA 19067

Dear Ms Fiordeliso:

Please refer to your supplemental new drug applications dated and received March 27, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PREZISTA® (darunavir) tablets:

Application	Supplement	Study
NDA 21-976	S-012	TMC114-C214
NDA 21-976	S-013	TMC114-C211

We acknowledge receipt of your submissions dated July 14, 2009, July 17, 2009, August 26, 2009, September 16, 2009, September 28, 2009, January 15, 2010 and January 26, 2010.

These Prior Approval supplemental new drug applications provide for updates to the U.S. Package Insert and Patient Package Insert with 96 week data from two trials, one in treatment-experienced patients and one in treatment-naïve patients to support the use of PREZISTA® (darunavir) tablets for the treatment of HIV-1 infection.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert, text for the patient package insert). For administrative purposes, please designate this submission, “**SPL for approved NDA 21-976/S-012 and NDA 21-976/S-013**”.

## **LABELING**

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert).

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

## **LETTERS TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch  
Food and Drug Administration  
5600 Fishers Lane, Room 12B05  
Rockville, MD 20857

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacy Powers Newalu, M.P.H., Regulatory Project Manager, at (301) 796-3978.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.  
Director  
Division of Antiviral Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

Enclosure  
Content of Labeling

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-21976	SUPPL-13	CENTOCOR ORTHO BIOTECH INC	PREZISTA
NDA-21976	SUPPL-12	CENTOCOR ORTHO BIOTECH INC	PREZISTA

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

/s/

JEFFREY S MURRAY  
01/27/2010